DBV Stock (NASDAQ:DBVT)
Previous Close
$0.81
52W Range
$0.50 - $3.25
50D Avg
$0.89
200D Avg
$1.36
Market Cap
$76.97M
Avg Vol (3M)
$63.93K
Beta
0.88
Div Yield
-
DBVT Company Profile
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBVT Performance
Peer Comparison
Ticker | Company |
---|---|
NUVL | Nuvalent, Inc. |
CNTA | Centessa Pharmaceuticals plc |
IKNA | Ikena Oncology, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
INBX | Inhibrx, Inc. |
ORIC | ORIC Pharmaceuticals, Inc. |
IPHA | Innate Pharma S.A. |
HCWB | HCW Biologics Inc. |
MNOV | MediciNova, Inc. |
ITOS | iTeos Therapeutics, Inc. |
TARS | Tarsus Pharmaceuticals, Inc. |
RZLT | Rezolute, Inc. |
GNFT | Genfit S.A. |
ANEB | Anebulo Pharmaceuticals, Inc. |
EPIX | ESSA Pharma Inc. |
MOLN | Molecular Partners AG |
LYRA | Lyra Therapeutics, Inc. |
CELC | Celcuity Inc. |
OPT | Opthea Limited |
ELYM | Eliem Therapeutics, Inc. |